TELA
TELA Bio Inc

317
Mkt Cap
$42.08M
Volume
135,118.00
52W High
$2.96
52W Low
$0.8645
PE Ratio
-0.98
TELA Fundamentals
Price
$0.8717
Prev Close
$0.945
Open
$0.9454
50D MA
$1.09
Beta
0.78
Avg. Volume
60,553.75
EPS (Annual)
-$1.33
P/B
22.58
Rev/Employee
$331,578.95
Loading...
Loading...
News
all
press releases
Small Medtech TELA Bio Takes On Becton Dickinson, Alleges Hernia Mesh Monopoly
TELA Bio is suing Becton Dickinson for allegedly abusing its monopoly power in the hernia mesh market to limit competition and harm patients.read more...
Benzinga·1mo ago
News Placeholder
More News
News Placeholder
TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +17.65% and -17.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -200.00% and +1.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -22.22% and -1.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of +33.33% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -0.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Deutsche Bank initiates coverage on Telekom Austria with “hold” rating
investing.com·8mo ago
<
...
1
>

Latest TELA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.